RS53104A - Chemically-modified human growth hormone conjugates - Google Patents
Chemically-modified human growth hormone conjugatesInfo
- Publication number
- RS53104A RS53104A YU53104A YUP53104A RS53104A RS 53104 A RS53104 A RS 53104A YU 53104 A YU53104 A YU 53104A YU P53104 A YUP53104 A YU P53104A RS 53104 A RS53104 A RS 53104A
- Authority
- RS
- Serbia
- Prior art keywords
- chemically
- growth hormone
- human growth
- modified human
- hgh
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 5
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 5
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33190701P | 2001-11-20 | 2001-11-20 | |
| PCT/US2002/037270 WO2003044056A2 (fr) | 2001-11-20 | 2002-11-20 | Conjugues de l'hormone de croissance humaine chimiquement modifiee |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS53104A true RS53104A (en) | 2006-10-27 |
Family
ID=23295870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU53104A RS53104A (en) | 2001-11-20 | 2002-11-20 | Chemically-modified human growth hormone conjugates |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1453859A2 (fr) |
| JP (2) | JP2005525302A (fr) |
| KR (2) | KR20050044858A (fr) |
| CN (1) | CN1608079A (fr) |
| AP (1) | AP2004003050A0 (fr) |
| AU (1) | AU2002356990A1 (fr) |
| BR (1) | BR0214451A (fr) |
| CA (1) | CA2467731A1 (fr) |
| CO (1) | CO5580794A2 (fr) |
| EA (2) | EA008505B1 (fr) |
| EC (1) | ECSP045114A (fr) |
| GE (1) | GEP20063860B (fr) |
| HR (1) | HRP20040448A2 (fr) |
| HU (1) | HUP0500997A2 (fr) |
| IL (1) | IL162031A0 (fr) |
| IS (1) | IS7268A (fr) |
| MA (1) | MA27544A1 (fr) |
| MX (1) | MXPA04004809A (fr) |
| NO (1) | NO20042182L (fr) |
| OA (1) | OA13063A (fr) |
| PL (1) | PL374354A1 (fr) |
| RS (1) | RS53104A (fr) |
| TN (1) | TNSN04090A1 (fr) |
| WO (1) | WO2003044056A2 (fr) |
| ZA (1) | ZA200403907B (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| US7041855B2 (en) | 2001-12-11 | 2006-05-09 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| US6956135B2 (en) | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| AU2002357806A1 (en) * | 2001-12-11 | 2003-06-23 | Sun Bio, Inc. | Novel monofunctional polyethylene glycol aldehydes |
| US6916962B2 (en) | 2001-12-11 | 2005-07-12 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
| CA2473526C (fr) * | 2002-01-18 | 2013-10-22 | Biogen Idec Ma Inc. | Composes de polymere polyalkykene et leurs utilisations |
| EP1591467A1 (fr) * | 2002-09-09 | 2005-11-02 | Nektar Therapeutics Al, Corporation | Conjugue d un polyethylene glycol comprenant un group terminal alcanal et un hormone de croissance humaine |
| RS20050202A (en) | 2002-09-09 | 2007-08-03 | Nektar Therapeuticals Al.Corporation, | Water-soluble polymer alkanals |
| US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| US20050281778A1 (en) * | 2003-03-28 | 2005-12-22 | Myung-Ok Park | Human growth hormone conjugated with biocompatible polymer |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| WO2005034988A1 (fr) * | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Molecules a action prolongee contenues dans des formulations a liberation prolongee |
| CA2552043A1 (fr) * | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Conjugaison de peptides induite par la transglutaminase |
| EA200700380A1 (ru) * | 2004-08-31 | 2007-10-26 | Фармация Энд Апджон Компани Ллс | Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения |
| SG158148A1 (en) | 2004-12-22 | 2010-01-29 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| JP2008525473A (ja) | 2004-12-22 | 2008-07-17 | アンブレツクス・インコーポレイテツド | 修飾されたヒト成長ホルモン |
| MX2007007591A (es) * | 2004-12-22 | 2007-07-25 | Ambrx Inc | Metodos para expresion y purificacion de hormona de crecimiento humano recombinante. |
| US20090105134A1 (en) | 2005-02-10 | 2009-04-23 | Novo Nordisk A/S | C-Terminally Pegylated Growth Hormones |
| WO2006111524A2 (fr) | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Variantes de l'il-21 |
| JP2009506096A (ja) * | 2005-08-30 | 2009-02-12 | ノボ ノルディスク ヘルス ケア アーゲー | ペグ化成長ホルモンの液状調製物 |
| PL1954710T3 (pl) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie |
| CA2882445A1 (fr) | 2005-12-14 | 2007-06-21 | Ambrx, Inc. | Compositions contenant des acides amines et polypeptides non naturels, procedes mettant en jeu ceux-ci et utilisations de ceux-ci |
| RU2009103198A (ru) | 2006-07-07 | 2010-08-20 | Ново Нордиск Хелс Кеа Аг (Ch) | Новые белковые конъюгаты и способы их получения |
| CN101108895B (zh) * | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| AU2007310777A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | IL-21 variants |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| EP2272875B1 (fr) * | 2008-04-03 | 2014-01-15 | Biosteed Gene Expression Tech. CO., LTD. | Hormone de croissance modifiée par polyéthylèneglycol double brin, son procédé de préparation et son application |
| KR101104574B1 (ko) * | 2008-05-14 | 2012-01-11 | 성균관대학교산학협력단 | 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도 |
| TWI421093B (zh) * | 2008-07-31 | 2014-01-01 | Pharmaessentia Corp | 胜肽－聚合物綴合物 |
| JP5977945B2 (ja) | 2008-08-06 | 2016-08-24 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有するコンジュゲートタンパク質 |
| RU2409669C9 (ru) * | 2008-08-18 | 2012-05-27 | ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") | Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами |
| JP5766118B2 (ja) * | 2008-09-11 | 2015-08-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法 |
| CN102292349B (zh) | 2009-01-22 | 2016-04-13 | 诺沃—诺迪斯克保健股份有限公司 | 稳定的生长激素化合物 |
| JP6086528B2 (ja) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| RU2012129674A (ru) | 2009-12-15 | 2014-01-27 | Аспендис Фарма Ас | Композиция гормона роста |
| AU2011208625C1 (en) | 2010-01-22 | 2022-08-18 | Novo Nordisk Health Care Ag | Growth hormones with prolonged in-vivo efficacy |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| JP2013533217A (ja) * | 2010-05-17 | 2013-08-22 | セビックス・インコーポレイテッド | Ｐｅｇ化ｃ−ペプチド |
| EP2446898A1 (fr) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés |
| EA019967B1 (ru) * | 2011-12-21 | 2014-07-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| CN107530403A (zh) | 2014-11-06 | 2018-01-02 | 药华医药股份有限公司 | 用于长效型干扰素的剂量方案 |
| HUE056849T2 (hu) | 2014-11-21 | 2022-03-28 | Ascendis Pharma Endocrinology Div A/S | Hosszú hatástartalmú növekedési hormon adagolási formák |
| IL254389B2 (en) * | 2015-03-11 | 2023-03-01 | Nektar Therapeutics | Polymer conjugates and the il–7 group |
| KR102152437B1 (ko) * | 2015-09-18 | 2020-09-07 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 장시간 작용형 아드레노메둘린 유도체 |
| CN114539384B (zh) * | 2020-11-19 | 2024-09-06 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| DE69128944T2 (de) * | 1990-05-04 | 1998-06-25 | American Cyanamid Co | Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten |
| WO1992016555A1 (fr) * | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Conjuges de polypeptides et de glycopolypeptides associes a des polymeres, contenant de l'hydrazine |
| AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
| NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| AU718439B2 (en) * | 1995-09-21 | 2000-04-13 | Genentech Inc. | Human growth hormone variants |
| ES2297889T3 (es) * | 1997-07-14 | 2008-05-01 | Bolder Biotechnology, Inc. | Derivados de hormona de crecimiento y proteinas relacionadas. |
| BR122013003013B8 (pt) * | 1999-01-14 | 2021-07-06 | Bolder Biotechnology Inc | proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção |
| HU228488B1 (en) * | 1999-01-29 | 2013-03-28 | Amgen Inc | Gcsf conjugates |
| AU2001289307A1 (en) * | 2000-04-06 | 2001-10-23 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
| AU2002219021A1 (en) * | 2001-01-11 | 2002-07-24 | Maxygen Aps | Variant growth hormone molecules conjugated with macromolecular compounds |
-
2002
- 2002-11-20 EA EA200400565A patent/EA008505B1/ru unknown
- 2002-11-20 HU HU0500997A patent/HUP0500997A2/hu unknown
- 2002-11-20 BR BRPI0214451-4A patent/BR0214451A/pt not_active IP Right Cessation
- 2002-11-20 AU AU2002356990A patent/AU2002356990A1/en not_active Abandoned
- 2002-11-20 WO PCT/US2002/037270 patent/WO2003044056A2/fr not_active Application Discontinuation
- 2002-11-20 EA EA200700431A patent/EA200700431A1/ru unknown
- 2002-11-20 EP EP02803695A patent/EP1453859A2/fr not_active Withdrawn
- 2002-11-20 PL PL02374354A patent/PL374354A1/xx unknown
- 2002-11-20 MX MXPA04004809A patent/MXPA04004809A/es not_active Application Discontinuation
- 2002-11-20 AP APAP/P/2004/003050A patent/AP2004003050A0/en unknown
- 2002-11-20 GE GE5599A patent/GEP20063860B/en unknown
- 2002-11-20 JP JP2003545691A patent/JP2005525302A/ja active Pending
- 2002-11-20 RS YU53104A patent/RS53104A/sr unknown
- 2002-11-20 KR KR1020047007708A patent/KR20050044858A/ko active IP Right Grant
- 2002-11-20 IL IL16203102A patent/IL162031A0/xx unknown
- 2002-11-20 CN CNA028259289A patent/CN1608079A/zh active Pending
- 2002-11-20 OA OA1200400143A patent/OA13063A/en unknown
- 2002-11-20 CA CA002467731A patent/CA2467731A1/fr not_active Abandoned
- 2002-11-20 KR KR1020077011730A patent/KR20070072924A/ko not_active Application Discontinuation
-
2004
- 2004-05-17 IS IS7268A patent/IS7268A/is unknown
- 2004-05-19 MA MA27686A patent/MA27544A1/fr unknown
- 2004-05-20 ZA ZA200403907A patent/ZA200403907B/en unknown
- 2004-05-20 CO CO04046633A patent/CO5580794A2/es not_active Application Discontinuation
- 2004-05-20 HR HR20040448A patent/HRP20040448A2/hr not_active Application Discontinuation
- 2004-05-20 EC EC2004005114A patent/ECSP045114A/es unknown
- 2004-05-20 TN TNP2004000090A patent/TNSN04090A1/fr unknown
- 2004-05-26 NO NO20042182A patent/NO20042182L/no not_active Application Discontinuation
-
2006
- 2006-07-14 JP JP2006193577A patent/JP2006321808A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050044858A (ko) | 2005-05-13 |
| MA27544A1 (fr) | 2005-10-03 |
| EA200700431A1 (ru) | 2008-02-28 |
| IL162031A0 (en) | 2005-11-20 |
| NO20042182L (no) | 2004-08-11 |
| ECSP045114A (es) | 2004-07-23 |
| OA13063A (en) | 2006-11-10 |
| EA200400565A1 (ru) | 2005-06-30 |
| ZA200403907B (en) | 2007-12-27 |
| JP2005525302A (ja) | 2005-08-25 |
| AP2004003050A0 (en) | 2004-06-30 |
| GEP20063860B (en) | 2006-06-26 |
| HRP20040448A2 (en) | 2006-02-28 |
| IS7268A (is) | 2004-05-17 |
| EA008505B1 (ru) | 2007-06-29 |
| CN1608079A (zh) | 2005-04-20 |
| AU2002356990A1 (en) | 2003-06-10 |
| BR0214451A (pt) | 2006-05-30 |
| PL374354A1 (en) | 2005-10-17 |
| MXPA04004809A (es) | 2004-08-11 |
| WO2003044056A3 (fr) | 2003-08-21 |
| TNSN04090A1 (fr) | 2006-06-01 |
| CA2467731A1 (fr) | 2003-05-30 |
| CO5580794A2 (es) | 2005-11-30 |
| KR20070072924A (ko) | 2007-07-06 |
| EP1453859A2 (fr) | 2004-09-08 |
| HUP0500997A2 (en) | 2007-11-28 |
| JP2006321808A (ja) | 2006-11-30 |
| WO2003044056A2 (fr) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04004809A (es) | Conjugados de hormona de crecimiento humana modificada quimicamente. | |
| MXPA05004993A (es) | Conjugados de hormona del crecimiento humana modificados quimicamente. | |
| DK1715887T3 (da) | N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf | |
| MX344559B (es) | Compuestos de hormona de crecimiento humana recombinante unidos al peg. | |
| WO2002057293A3 (fr) | Protéines de liaison en doigt de gant modifiées | |
| YU101503A (en) | A novel engineered superantigen for human therapy | |
| AU2003303598A1 (en) | Compositions, methods, and systems for inferring bovine breed | |
| EP2279754A3 (fr) | Remodelage et glycoconjugation de hormone de croissance humaine (hGH) | |
| PL370310A1 (en) | Method of improving the growth performance of an animal | |
| EP2107071A3 (fr) | Iimmunoglobulines anti-epcam | |
| WO2001076639A3 (fr) | Conjugues de myelopoietine modifies chimiquement | |
| MXPA04000068A (es) | Conjugados de progenipoyetina modificados quimicamente. | |
| MXPA04002103A (es) | Una proteina de union a caspasa-8, su preparacion y uso. | |
| AU2001233912A1 (en) | Diagnosis of breast cancer using bcmp-81 as marker | |
| WO2002099438A3 (fr) | Modulation de la fixation des hormones steroides | |
| HK1082510A1 (en) | Promoter to il-18bp, its preparation and use | |
| MXPA03007002A (es) | Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida. | |
| TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
| AU2001274138A1 (en) | Propanolaminotetralines, preparation thereof and compositions containing same | |
| EP1437364A3 (fr) | Polypeptide se liant au recepteur androgène et son utilisation potentielle dans le traitement du cancer du sein | |
| YANG et al. | Transmembrane TNF-α increases over soluble TNF-α in human lung cancer tissue | |
| TW200635953A (en) | Specific binding agents of human angiopoietin-2 |